Breast Cancer Research and Treatment

Effect of prior treatments on post-CDK 4/6 inhibitor survival in hormone receptor-positive breast cancer.  197:673-681. 2023

A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer 2023

Mitigating disparities in breast cancer treatment at an academic safety-net hospital 2023

Co-occurrence and metabolic biomarkers of sensory and motor subtypes of peripheral neuropathy from paclitaxel.  194:551-560. 2022

Exclusion criteria of breast cancer clinical trial protocols: a descriptive analysis.  191:471-475. 2022

Clinical trial representativeness and treatment intensity in a real-world sample of women with early stage breast cancer.  190:531-540. 2021

Characterization of estrogen receptor-low-positive breast cancer.  188:225-235. 2021

A qualitative study to evaluate physician attitudes regarding omission of surgery among exceptional responders to neoadjuvant systemic therapy for breast cancer (NRG-CC006).  187:777-784. 2021

Myosteatosis evaluation using erector spinae and psoas muscles to predict adverse events during adjuvant chemotherapy for breast cancer.  186:487-495. 2021

Should we be talking about guidelines with patients? A qualitative analysis in metastatic breast cancer.  184:115-121. 2020

The association of body composition parameters and adverse events in women receiving chemotherapy for early breast cancer.  182:631-642. 2020

Does oncoplastic surgery increase immediate (30-day) postoperative complications? An analysis of the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) database.  182:429-438. 2020

Association of body composition with function in women with early breast cancer.  181:411-421. 2020

Primary and secondary breast angiosarcoma: single center report and a meta-analysis.  178:523-533. 2019

Muscle composition and outcomes in patients with breast cancer: meta-analysis and systematic review.  177:569-579. 2019

Adult weight gain accelerates the onset of breast cancer.  176:649-656. 2019

LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.  171:637-648. 2018

A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer.  170:677-685. 2018

Randomized trial of proactive rapid genetic counseling versus usual care for newly diagnosed breast cancer patients..  170:517-524. 2018

Circulating microRNAs from the miR-106a–363 cluster on chromosome X as novel diagnostic biomarkers for breast cancer.  170:257-270. 2018

Thirty-day postoperative morbidity and mortality in elderly women with breast cancer: an analysis of the NSQIP database.  170:373-379. 2018

Evaluation of [ ⁸⁹ Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer.  169:523-530. 2018

Speed of processing in middle aged and older breast cancer survivors (SOAR): A feasibility study. 2018

Speed of processing training in middle-aged and older breast cancer survivors (SOAR): results of a randomized controlled pilot.  168:259-267. 2018

Ethnicity and breast cancer characteristics in Kenya.  167:425-437. 2018

Healthcare utilization, Medicare spending, and sources of patient distress identified during implementation of a lay navigation program for older patients with breast cancer.  167:215-223. 2018

Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.  167:89-99. 2018

Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008.  167:107-116. 2018

Effects of a multicomponent physical activity behavior change intervention on breast cancer survivor health status outcomes in a randomized controlled trial.  159:283-291. 2016

Weight gain during adjuvant endocrine treatment for early-stage breast cancer: What is the evidence?.  158:203-217. 2016

Great tumour burden in the axilla may influence lymphatic drainage in breast cancer patients.  157:503-510. 2016

Racial disparities in individual breast cancer outcomes by hormone-receptor subtype, area-level socio-economic status and healthcare resources.  157:575-586. 2016

Telomeric G-quadruplex-forming DNA fragments induce TLR9-mediated and LL-37-regulated invasion in breast cancer cells in vitro.  155:261-271. 2016

Quality of life outcomes from the Exercise and Nutrition Enhance Recovery and Good Health for You (ENERGY)-randomized weight loss trial among breast cancer survivors.  154:329-337. 2015

PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers.  150:569-579. 2015

Effects of the BEAT Cancer physical activity behavior change intervention on physical activity, aerobic fitness, and quality of life in breast cancer survivors: a multicenter randomized controlled trial.  149:109-119. 2015

Taking the next step: a systematic review and meta-analysis of physical activity and behavior change interventions in recent post-treatment breast cancer survivors.  149:331-342. 2015

A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007.  148:99-106. 2014

Recurrent read-through fusion transcripts in breast cancer.  146:287-297. 2014

TBCRC 018: Phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.  146:557-566. 2014

DNA from dead cancer cells induces TLR9-mediated invasion and inflammation in living cancer cells.  142:477-487. 2013

Multivitamin and mineral use and breast cancer mortality in older women with invasive breast cancer in the women's health initiative.  141:495-505. 2013

Time-trends in survival in young women with breast cancer in a SEER population-based study.  138:241-248. 2013

Advanced cognitive training for breast cancer survivors: A randomized controlled trial.  135:799-809. 2012

Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer.  135:481-493. 2012

Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity.  133:437-445. 2012

Effect of anti-DR5 and chemotherapy on basal-like breast cancer.  133:417-426. 2012

Bone metastasis in a novel breast cancer mouse model containing human breast and human bone.  132:471-486. 2012

Chemotherapy response and recurrence-free survival in Neoadjuvant breast cancer depends on biomarker profiles: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).  132:1049-1062. 2012

Locally advanced breast cancers are more likely to present as interval cancers: Results from the I-SPY 1 TRIAL (CALGB 150007/150012, acrin 6657, interSPORE trial).  132:871-879. 2012

Bloody nipple discharge is a predictor of breast cancer risk: A meta-analysis.  132:9-14. 2012

Adjuvant therapy for HER2+ breast cancer: Practice, perception, and toxicity.  131:713-721. 2012

Mortality following bone metastasis and skeletal-related events among women with breast cancer: A population-based analysis of U.S. Medicare beneficiaries, 1999-2006.  131:231-238. 2012

Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: Results of four randomized trials.  128:625-631. 2011

Out of pocket cost comparison between Caucasian and minority breast cancer survivors in the Breast Cancer Education Intervention (BCEI).  127:521-529. 2011

A novel synthetic iminoquinone, BA-TPQ, as an anti-breast cancer agent: In vitro and in vivo activity and mechanisms of action.  123:321-331. 2010

Gli1 promotes cell survival and is predictive of a poor outcome in ERα-negative breast cancer.  123:59-71. 2010

A novel orthotopic and metastatic mouse model of breast cancer in human mammary microenvironment.  120:337-344. 2010

Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational control.  108:43-55. 2008

Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma.  105:157-167. 2007

Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer.  104:341-349. 2007

Telomerase immortalization of human mammary epithelial cells derived from a BRCA2 mutation carrier.  99:103-115. 2006

Gene 33 inhibits apoptosis of breast cancer cells and increases poly(ADP-ribose) polymerase expression.  91:207-215. 2005

Inhibin A and B as predictive markers for chemotherapy-induced premature ovarian failure (POF) among premenopausal women with early stage breast cancer (ESBC)..  94:S47-S47. 2005

Omega-3 fatty acids decrease protein kinase expression in human breast cancer cells.  67:279-283. 2001

The chemopreventive properties of soy isoflavonoids in animal models of breast cancer.  46:169-179. 1997

Gene therapy strategies for carcinoma of the breast.  44:93-114. 1997

Fluorescent in situ hybridization assessment of chromosome 8 copy number in breast cancer.  38:201-208. 1996

A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer - A Southeastern Cancer Study Group Project.  3:209-220. 1983

Postmastectomy adjuvant chemotherapy with or without radiation therapy in women with operable breast cancer and positive axillary lymph nodes: The Southeastern Cancer Study Group experience.  3. 1983

A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer.  2:93-99. 1982

Multivariate prognostic factor analysis evaluating dose received in patients with advanced breast cancer treated with a doxorubicin combination.  1. 1981